These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26158171)

  • 1. Treatment Outcomes and Predictors of Response in Treatment-Naive HCV Patients Treated with Peginterferon Alfa/Ribavirin in Real-World Italian Clinics: Sub-Analysis from the PROPHESYS Cohort.
    Ascione A; Bruno S; Coppola C; Mangia A; Orlandini A; Schmitz M; Deodato B; Puoti M
    Hepatogastroenterology; 2014 Jun; 61(132):1094-106. PubMed ID: 26158171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.
    Foster GR; Coppola C; Derbala M; Ferenci P; Orlandini A; Reddy KR; Tallarico L; Shiffman ML; Ahlers S; Bakalos G; Hassanein T;
    PLoS One; 2016; 11(3):e0151703. PubMed ID: 27018988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
    Dore GJ; Lawitz E; Hézode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Tran A; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey D; Pol S; Harley H; George J; Fung SK; de Lédinghen V; Hagens P; McPhee F; Hernandez D; Cohen D; Cooney E; Noviello S; Hughes EA
    Gastroenterology; 2015 Feb; 148(2):355-366.e1. PubMed ID: 25311593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials.
    Marcellin P; Cheinquer H; Curescu M; Dusheiko GM; Ferenci P; Horban A; Jensen D; Lengyel G; Mangia A; Ouzan D; Puoti M; Rodriguez-Torres M; Shiffman ML; Schmitz M; Tatsch F; Rizzetto M
    Hepatology; 2012 Dec; 56(6):2039-50. PubMed ID: 22706730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions.
    Mangia A; Bányai T; De Bartolomeo G; Gervain J; Habersetzer F; Mulkay JP; Ouzan D; Parruti G; Passariello N; Remy AJ; Rizzetto M; Shiffman ML; Tice AD; Schmitz M; Tatsch F; Rodriguez-Torres M
    Liver Int; 2014 Aug; 34(7):e217-28. PubMed ID: 24251988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort.
    Aronsohn A; Ancuta I; Caruntu F; Coppola C; Delic D; Digiacomo A; Dusheiko GM; Lengyel G; Marcellin P; Orlandini A; Pruthi J; Silva GF; Tallarico L; Schmitz M; Tatsch F; Korner E; Cheinquer H
    J Viral Hepat; 2014 May; 21(5):377-80. PubMed ID: 24131506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection.
    Suzuki F; Toyota J; Ikeda K; Chayama K; Mochida S; Hayashi N; Ishikawa H; Miyagoshi H; Hu W; McPhee F; Hughes EA; Kumada H
    Antivir Ther; 2014; 19(5):491-9. PubMed ID: 24451122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study.
    Craxì A; Piccinino F; Ciancio A; Iannacone C; Deodato B; Golotta C; Ascione A
    Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):388-95. PubMed ID: 24569819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHESYS study.
    D'heygere F; George C; Habersetzer F; Tripathi D; Q Pan C; Giron JA; Schmitz M; Tatsch F
    Ann Hepatol; 2014; 13(2):303-4. PubMed ID: 24558225
    [No Abstract]   [Full Text] [Related]  

  • 10. Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1.
    Izumi N; Yokosuka O; Kawada N; Osaki Y; Yamamoto K; Sata M; Ishikawa H; Ueki T; Hu W; McPhee F; Hughes EA; Kumada H
    Antivir Ther; 2014; 19(5):501-10. PubMed ID: 24451151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies.
    Kumada H; Mochida S; Suzuki F; Chayama K; Karino Y; Nakamura K; Fujimoto G; Howe AY; Ludmerer SW; Mobashery N
    J Gastroenterol Hepatol; 2016 Oct; 31(10):1674-1683. PubMed ID: 26936417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
    Berak H; Laskus T; Kołakowska-Rządzka A; Wasilewski M; Stańczak JJ; Bardadin K; Walewska-Zielecka B; Horban A
    Adv Med Sci; 2014 Sep; 59(2):261-5. PubMed ID: 25117425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.
    Rodriguez-Torres M; Jeffers LJ; Sheikh MY; Rossaro L; Ankoma-Sey V; Hamzeh FM; Martin P;
    N Engl J Med; 2009 Jan; 360(3):257-67. PubMed ID: 19144941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.
    McPhee F; Hernandez D; Zhou N; Yu F; Ueland J; Monikowski A; Chayama K; Toyota J; Izumi N; Yokosuka O; Kawada N; Osaki Y; Hughes EA; Watanabe H; Ishikawa H; Kumada H
    Antivir Ther; 2014; 19(5):479-90. PubMed ID: 24448487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis.
    Gane EJ; Rouzier R; Hassanein T; Stedman CA; Mazur W; Kupcova V; Le Pogam S; Eng S; Voulgari A; Morcos PN; Brennan BJ; Scalori A; Thommes J
    Hepatol Int; 2016 May; 10(3):478-87. PubMed ID: 26886127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea.
    Wei L; Han T; Yang D; Heo J; Shang J; Cheng J; Chen X; Xie Q; Kim JH; Kalmeijer R; Ouwerkerk-Mahadevan S; Hoeben E; Lenz O; Verbinnen T; Sinha R; Li M; Scott J; Peeters M; Witek J;
    J Gastroenterol Hepatol; 2016 May; 31(5):912-20. PubMed ID: 26777137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis.
    Kao JH; Tung SY; Lee Y; Thongsawat S; Tanwandee T; Sheen IS; Wu JJ; Li H; Brennan BJ; Zhou J; Le Pogam S; Najera I; Thommes JA; Hill G
    J Gastroenterol Hepatol; 2016 Oct; 31(10):1757-1765. PubMed ID: 26992248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
    Rustgi VK; Esposito S; Hamzeh FM; Shiffman ML
    Aliment Pharmacol Ther; 2008 Mar; 27(5):433-40. PubMed ID: 18081737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin.
    Ferenci P; Aires R; Ancuta I; Arohnson A; Cheinquer H; Delic D; Gschwantler M; Larrey D; Tallarico L; Schmitz M; Tatsch F; Ouzan D
    Liver Int; 2014 Nov; 34(10):1550-9. PubMed ID: 24329937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.